Cancer Genes in Lung Cancer: Racial Disparities: Are There Any?

Genes and Cancer

Volumn 3, Issue 7-8, 2012, Pages 467-480

  El Telbany, Ahmed ^a,b   Ma, Patrick C ^a,c  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

cancer gene; lung cancer; racial disparities; targeted therapy

Indexed keywords

ALK GENE; ALTERNATIVE RNA SPLICING; BRAF GENE; CANCER GENETICS; CANCER GROWTH; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; COPY NUMBER VARIATION; DEMOGRAPHY; DRUG RESISTANCE; DRUG SENSITIVITY; EGFR GENE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; INCIDENCE; LKBI GENE; LUNG CANCER; LUNG CARCINOGENESIS; MET GENE; MISSENSE MUTATION; NONSENSE MUTATION; ONCOGENE K RAS; PIK3CA GENE; PRIORITY JOURNAL; RACE DIFFERENCE; RET GENE; REVIEW; ROSI GENE; TUMOR GENE;

EID: 84875278514     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912465177     Document Type: Review

References (146)

1. Siegel R,Ward E,Brawley O,Jemal A.Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.CA Cancer J Clin. 2011;61:212-36.
2. Choong NW,Ma PC,Salgia R.Therapeutic targeting of receptor tyrosine kinases in lung cancer.Expert Opin Ther Targets. 2005;9:533-59.
3. Pao W,Kris MG,Iafrate AJ, et al.Integration of molecular profiling into the lung cancer clinic.Clin Cancer Res. 2009;15:5317-22.
4. Hardy D,Liu CC,Xia R, et al.Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer.Cancer. 2009;115:2199-211.
5. Gadgeel SM,Severson RK,Kau Y,Graff J,Weiss LK,Kalemkerian GP.Impact of race in lung cancer: analysis of temporal trends from a surveillance, epidemiology, and end results database.Chest. 2001;120:55-63.
6. Schwartz AG,Swanson GM.Lung carcinoma in African Americans and whites: a population-based study in metropolitan Detroit, Michigan.Cancer. 1997;79:45-52.
7. Weir BA,Woo MS,Getz G, et al.Characterizing the cancer genome in lung adenocarcinoma.Nature. 2007;450:893-8.
8. Tang X,Kadara H,Behrens C, et al.Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis.Clin Cancer Res. 2011;17:2434-43.
9. Broet P,Dalmasso C,Tan EH, et al.Genomic profiles specific to patient ethnicity in lung adenocarcinoma.Clin Cancer Res. 2011;17:3542-50.
10. Job B,Bernheim A,Beau-Faller M, et al.Genomic aberrations in lung adenocarcinoma in never smokers.PLoS One. 2010;5:e15145.
11. Modrek B,Ge L,Pandita A, et al.Oncogenic activating mutations are associated with local copy gain.Mol Cancer Res. 2009;7:1244-52.
12. Davies H,Bignell GR,Cox C, et al.Mutations of the BRAF gene in human cancer.Nature. 2002;417:949-54.
13. Ding L,Getz G,Wheeler DA, et al.Somatic mutations affect key pathways in lung adenocarcinoma.Nature. 2008;455:1069-75.
14. Lynch TJ,Bell DW,Sordella R, et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N Engl J Med. 2004;350:2129-39.
15. Paez JG,Janne PA,Lee JC, et al.EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.Science. 2004;304:1497-500.
16. Pao W,Miller V,Zakowski M, et al.EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.Proc Natl Acad Sci U S A. 2004;101:13306-11.
17. Choong NW,Dietrich S,Seiwert TY, et al.Gefitinib response of erlotinib-refractory lung cancer involving meninges: role of EGFR mutation.Nat Clin Pract Oncol. 2006;3:50-7.
18. Tang Z,Jiang S,Du R, et al.Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.Oncogene. 2009;28:518-33.
19. Gazdar AF,Shigematsu H,Herz J,Minna JD.Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?.Trends Mol Med. 2004;10:481-6.
20. Shigematsu H,Gazdar AF.Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.Int J Cancer. 2006;118:257-62.
21. Eberhard DA,Johnson BE,Amler LC, et al.Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.J Clin Oncol. 2005;23:5900-9.
22. Bell DW,Lynch TJ,Haserlat SM, et al.Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.J Clin Oncol. 2005;23:8081-92.
23. Zhou W,Christiani DC.East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians.Chin J Cancer. 2011;30:287-92.
24. Kosaka T,Yatabe Y,Endoh H,Kuwano H,Takahashi T,Mitsudomi T.Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.Cancer Res. 2004;64:8919-23.
25. Tokumo M,Toyooka S,Kiura K, et al.The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.Clin Cancer Res. 2005;11:1167-73.
26. Sonobe M,Manabe T,Wada H,Tanaka F.Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma.Br J Cancer. 2005;93:355-63.
27. Huang SF,Liu HP,Li LH, et al.High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.Clin Cancer Res. 2004;10:8195-203.
28. Soung YH,Lee JW,Kim SY, et al.Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.Virchows Arch. 2005;446:483-8.
29. Shigematsu H,Lin L,Takahashi T, et al.Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.J Natl Cancer Inst. 2005;97:339-46.
30. Sugio K,Uramoto H,Ono K, et al.Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking.Br J Cancer. 2006;94:896-903.
31. Li C,Fang R,Sun Y, et al.Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.PLoS One. 2011;6:e28204.
32. Kim HR,Shim HS,Chung JH, et al.Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.Cancer. 2012;118:729-39.
33. Ren S,Kuang P,Zheng L, et al.Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.Cell Biochem Biophys.
34. Mok TS,Wu YL,Thongprasert S, et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med. 2009;361:947-57.
35. Keedy VL,Temin S,Somerfield MR, et al.American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.J Clin Oncol. 2011;29:2121-7.
36. Yatabe Y,Takahashi T,Mitsudomi T.Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer.Cancer Res. 2008;68:2106-11.
37. Varella-Garcia M.Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay.Diagn Pathol. 2006;1:19.
38. Cappuzzo F,Hirsch FR,Rossi E, et al.Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.J Natl Cancer Inst. 2005;97:643-55.
39. Kobayashi S,Boggon TJ,Dayaram T, et al.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.N Engl J Med. 2005;352:786-92.
40. Pao W,Miller VA,Politi KA, et al.Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.PLoS Med. 2005;2:e73.
41. Mulloy R,Ferrand A,Kim Y, et al.Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.Cancer Res. 2007;67:2325-30.
42. Kosaka T,Yatabe Y,Endoh H, et al.Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.Clin Cancer Res. 2006;12:5764-9.
43. Greulich H,Chen TH,Feng W, et al.Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.PLoS Med. 2005;2:e313.
44. Tokumo M,Toyooka S,Ichihara S, et al.Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.Lung Cancer. 2006;53:117-21.
45. Balak MN,Gong Y,Riely GJ, et al.Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.Clin Cancer Res. 2006;12:6494-501.
46. Leidner RS,Fu P,Clifford B, et al.Genetic abnormalities of the EGFR pathway in African American patients with non-small-cell lung cancer.J Clin Oncol. 2009;27:5620-6.
47. Harada T,Lopez-Chavez A,Xi L,Raffeld M,Wang Y,Giaccone G.Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry.Oncogene. 2011;30:1744-52.
48. Asahina H,Yamazaki K,Kinoshita I,Yokouchi H,Dosaka-Akita H,Nishimura M.Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L.Lung Cancer. 2006;54:419-22.
49. Chen YR,Fu YN,Lin CH, et al.Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.Oncogene. 2006;25:1205-15.
50. Engelman JA,Zejnullahu K,Mitsudomi T, et al.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.Science. 2007;316:1039-43.
51. Bean J,Brennan C,Shih JY, et al.MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.Proc Natl Acad Sci U S A. 2007;104:20932-7.
52. Sequist LV,Waltman BA,Dias-Santagata D, et al.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.Sci Transl Med. 2011;3:75ra26.
53. Abidoye O,Ferguson MK,Salgia R.Lung carcinoma in African Americans.Nat Clin Pract Oncol. 2007;4:118-29.
54. Yang SH,Mechanic LE,Yang P, et al.Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer.Clin Cancer Res. 2005;11:2106-10.
55. Cote ML,Haddad R,Edwards DJ, et al.Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer.J Thorac Oncol. 2011;6:627-30.
56. Reinersman JM,Johnson ML,Riely GJ, et al.Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.J Thorac Oncol. 2011;6:28-31.
57. Arrieta O,Cardona AF,Federico Bramuglia G, et al.Genotyping non-small cell lung cancer (NSCLC) in Latin America.J Thorac Oncol. 2011;6:1955-9.
58. Bacchi CE,Ciol H,Queiroga EM,Benine LC,Silva LH,Ojopi EB.Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.Clinics (Sao Paulo). 2012;67:419-24.
59. Han HS,Eom DW,Kim JH, et al.EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.Clin Lung Cancer. 2011;12:380-6.
60. Han C,Zou H,Ma J,Zhou Y,Zhao J.Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis.Zhongguo Fei Ai Za Zhi. 2010;13:882-91.
61. Kalikaki A,Koutsopoulos A,Trypaki M, et al.Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.Br J Cancer. 2008;99:923-9.
62. Monaco SE,Nikiforova MN,Cieply K,Teot LA,Khalbuss WE,Dacic S.A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases.Hum Pathol. 2010;41:94-102.
63. Shepherd FA.Molecular selection trumps clinical selection.J Clin Oncol. 2011;29:2843-4.
64. Aviel-Ronen S,Blackhall FH,Shepherd FA,Tsao MS.K-ras mutations in non-small-cell lung carcinoma: a review.Clin Lung Cancer. 2006;8:30-8.
65. Marchetti A,Martella C,Felicioni L, et al.EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.J Clin Oncol. 2005;23:857-65.
66. Toyooka S,Tokumo M,Shigematsu H, et al.Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers.Cancer Res. 2006;66:1371-5.
67. Toyooka S,Yatabe Y,Tokumo M, et al.Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung.Int J Cancer. 2006;118:1588-90.
68. Pao W,Wang TY,Riely GJ, et al.KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.PLoS Med. 2005;2:e17.
69. Riely GJ,Kris MG,Rosenbaum D, et al.Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.Clin Cancer Res. 2008;14:5731-4.
70. Sun Y,Ren Y,Fang Z, et al.Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.J Clin Oncol. 2010;28:4616-20.
71. Linardou H,Dahabreh IJ,Kanaloupiti D, et al.Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.Lancet Oncol. 2008;9:962-72.
72. Mao C,Qiu LX,Liao RY, et al.KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.Lung Cancer. 2010;69:272-8.
73. Hunt JD,Strimas A,Martin JE, et al.Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens.Cancer Epidemiol Biomarkers Prev. 2002;11:1405-12.
74. Ma PC,Maulik G,Christensen J,Salgia R.c-Met: structure, functions and potential for therapeutic inhibition.Cancer Metastasis Rev. 2003;22:309-25.
75. Wojta J,Nakamura T,Fabry A, et al.Hepatocyte growth factor stimulates expression of plasminogen activator inhibitor type 1 and tissue factor in HepG2 cells.Blood. 1994;84:151-7.
76. Dunsmore SE,Rubin JS,Kovacs SO,Chedid M,Parks WC,Welgus HG.Mechanisms of hepatocyte growth factor stimulation of keratinocyte metalloproteinase production.J Biol Chem. 1996;271:24576-82.
77. Besser D,Bardelli A,Didichenko S, et al.Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2.Oncogene. 1997;14:705-11.
78. Rikova K,Guo A,Zeng Q, et al.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.Cell. 2007;131:1190-203.
79. Guo A,Villen J,Kornhauser J, et al.Signaling networks assembled by oncogenic EGFR and c-Met.Proc Natl Acad Sci U S A. 2008;105:692-7.
80. Tang Z,Du R,Jiang S, et al.Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.Br J Cancer. 2008;99:911-22.
81. Schmidt L,Duh FM,Chen F, et al.Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.Nat Genet. 1997;16:68-73.
82. Schmidt L,Junker K,Nakaigawa N, et al.Novel mutations of the MET proto-oncogene in papillary renal carcinomas.Oncogene. 1999;18:2343-50.
83. Schmidt L,Junker K,Weirich G, et al.Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.Cancer Res. 1998;58:1719-22.
84. Ma PC,Kijima T,Maulik G, et al.c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.Cancer Res. 2003;63:6272-81.
85. Ma PC,Jagadeeswaran R,Jagadeesh S, et al.Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.Cancer Res. 2005;65:1479-88.
86. Zaffaroni D,Spinola M,Galvan A, et al.Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis.Oncogene. 2005;24:1084-90.
87. Kong-Beltran M,Seshagiri S,Zha J, et al.Somatic mutations lead to an oncogenic deletion of met in lung cancer.Cancer Res. 2006;66:283-9.
88. Lee JH,Gao CF,Lee CC,Kim MD,Vande Woude GF.An alternatively spliced form of Met receptor is tumorigenic.Exp Mol Med. 2006;38:565-73.
89. Krishnaswamy S,Kanteti R,Duke-Cohan JS, et al.Ethnic differences and functional analysis of MET mutations in lung cancer.Clin Cancer Res. 2009;15:5714-23.
90. Graveel CR,DeGroot JD,Sigler RE,Vande Woude GF.Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles.PLoS One. 2010;5:e13586.
91. Okuda K,Sasaki H,Yukiue H,Yano M,Fujii Y.Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer.Cancer Sci. 2008;99:2280-5.
92. Knudsen BS,Vande Woude G.Showering c-MET-dependent cancers with drugs.Curr Opin Genet Dev. 2008;18:87-96.
93. Feng Y,Thiagarajan PS,Ma PC.MET signaling: novel targeted inhibition and its clinical development in lung cancer.J Thorac Oncol. 2012;7:459-67.
94. Smolen GA,Sordella R,Muir B, et al.Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.Proc Natl Acad Sci U S A. 2006;103:2316-21.
95. Xie Q,Bradley R,Kang L, et al.Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.Proc Natl Acad Sci U S A. 2012;109:570-5.
96. Berthou S,Aebersold DM,Schmidt LS, et al.The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.Oncogene. 2004;23:5387-93.
97. Gherardi E,Birchmeier W,Birchmeier C,Vande Woude G.Targeting MET in cancer: rationale and progress.Nat Rev Cancer. 2012;12:89-103.
98. Sanchez-Cespedes M,Parrella P,Esteller M, et al.Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.Cancer Res. 2002;62:3659-62.
99. Matsumoto S,Iwakawa R,Takahashi K, et al.Prevalence and specificity of LKB1 genetic alterations in lung cancers.Oncogene. 2007;26:5911-8.
100. Koivunen JP,Kim J,Lee J, et al.Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.Br J Cancer. 2008;99:245-52.
101. Gao B,Sun Y,Zhang J, et al.Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung adenocarcinomas.J Thorac Oncol. 2010;5:1130-5.
102. Onozato R,Kosaka T,Achiwa H, et al.LKB1 gene mutations in Japanese lung cancer patients.Cancer Sci. 2007;98:1747-51.
103. Launonen V,Avizienyte E,Loukola A, et al.No evidence of Peutz-Jeghers syndrome gene LKB1 involvement in left-sided colorectal carcinomas.Cancer Res. 2000;60:546-8.
104. Suzuki Y,Oonishi T,Kudo T,Doi H.LKB1, TP16, EGFR, and KRAS somatic mutations in lung adenocarcinomas from a Chiba Prefecture, Japan cohort.Drug Discov Ther. 2012;6:24-30.
105. Gill RK,Yang SH,Meerzaman D, et al.Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer.Oncogene. 2011;30:3784-91.
106. Ji H,Ramsey MR,Hayes DN, et al.LKB1 modulates lung cancer differentiation and metastasis.Nature. 2007;448:807-10.
107. Naoki K,Chen TH,Richards WG,Sugarbaker DJ,Meyerson M.Missense mutations of the BRAF gene in human lung adenocarcinoma.Cancer Res. 2002;62:7001-3.
108. Brose MS,Volpe P,Feldman M, et al.BRAF and RAS mutations in human lung cancer and melanoma.Cancer Res. 2002;62:6997-7000.
109. Pratilas CA,Hanrahan AJ,Halilovic E, et al.Genetic predictors of MEK dependence in non-small cell lung cancer.Cancer Res. 2008;68:9375-83.
110. Paik PK,Arcila ME,Fara M, et al.Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.J Clin Oncol. 2011;29:2046-51.
111. Samuels Y,Wang Z,Bardelli A, et al.High frequency of mutations of the PIK3CA gene in human cancers.Science. 2004;304:554.
112. Kawano O,Sasaki H,Endo K, et al.PIK3CA mutation status in Japanese lung cancer patients.Lung Cancer. 2006;54:209-15.
113. Morris SW,Kirstein MN,Valentine MB, et al.Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.Science. 1994;263:1281-4.
114. Soda M,Choi YL,Enomoto M, et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.Nature. 2007;448:561-6.
115. Takeuchi K,Choi YL,Soda M, et al.Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.Clin Cancer Res. 2008;14:6618-24.
116. Koivunen JP,Mermel C,Zejnullahu K, et al.EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.Clin Cancer Res. 2008;14:4275-83.
117. Choi YL,Takeuchi K,Soda M, et al.Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.Cancer Res. 2008;68:4971-6.
118. Takeuchi K,Choi YL,Togashi Y, et al.KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.Clin Cancer Res. 2009;15:3143-9.
119. Wong DW,Leung EL,So KK, et al.The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.Cancer. 2009;115:1723-33.
120. Inamura K,Takeuchi K,Togashi Y, et al.EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.J Thorac Oncol. 2008;3:13-7.
121. Inamura K,Takeuchi K,Togashi Y, et al.EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.Mod Pathol. 2009;22:508-15.
122. Shinmura K,Kageyama S,Tao H, et al.EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.Lung Cancer. 2008;61:163-9.
123. Jin G,Jeon HS,Lee EB, et al.EML4-ALK fusion gene in Korean non-small cell lung cancer.J Korean Med Sci. 2012;27:228-30.
124. Martelli MP,Sozzi G,Hernandez L, et al.EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.Am J Pathol. 2009;174:661-70.
125. Shaw AT,Yasothan U,Kirkpatrick P.Crizotinib.Nat Rev Drug Discov. 2011;10:897-8.
126. Shaw AT,Yeap BY,Solomon BJ, et al.Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.Lancet Oncol. 2011;12:1004-12.
127. Choi YL,Soda M,Yamashita Y, et al.EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.N Engl J Med. 2010;363:1734-9.
128. Sasaki T,Okuda K,Zheng W, et al.The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.Cancer Res. 2010;70:10038-43.
129. Lipson D,Capelletti M,Yelensky R, et al.Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.Nat Med. 2012;18:382-4.
130. Knowles PP,Murray-Rust J,Kjaer S, et al.Structure and chemical inhibition of the RET tyrosine kinase domain.J Biol Chem. 2006;281:33577-87.
131. Ciampi R,Nikiforov YE.RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.Endocrinology. 2007;148:936-41.
132. Nikiforov YE.Thyroid carcinoma: molecular pathways and therapeutic targets.Mod Pathol. 2008;21:S37-43.
133. Kohno T,Ichikawa H,Totoki Y, et al.KIF5B-RET fusions in lung adenocarcinoma.Nat Med. 2012;18:375-7.
134. Birchmeier C,Sharma S,Wigler M.Expression and rearrangement of the ROS1 gene in human glioblastoma cells.Proc Natl Acad Sci U S A. 1987;84:9270-4.
135. Birchmeier C,O'Neill K,Riggs M,Wigler M.Characterization of ROS1 cDNA from a human glioblastoma cell line.Proc Natl Acad Sci U S A. 1990;87:4799-803.
136. Bergethon K,Shaw AT,Ignatius Ou SH, et al.ROS1 rearrangements define a unique molecular class of lung cancers.J Clin Oncol. 2012;30:863-70.
137. Liu G,Gurubhagavatula S,Zhou W, et al.Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.Pharmacogenomics J. 2008;8:129-38.
138. Cusatis G,Gregorc V,Li J, et al.Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.J Natl Cancer Inst. 2006;98:1739-42.
139. Ichihara S,Toyooka S,Fujiwara Y, et al.The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.Int J Cancer. 2007;120:1239-47.
140. John T,Liu G,Tsao MS.Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.Oncogene. 2009;28:S14-23.
141. Chmielecki J,Peifer M,Jia P, et al.Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer.Nucleic Acids Res. 2010;38:6985-96.
142. Pleasance ED,Stephens PJ,O'Meara S, et al.A small-cell lung cancer genome with complex signatures of tobacco exposure.Nature. 2010;463:184-90.
143. Bae NC, et al.EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.Cancer Genet Cytogenet. 2007;173 (2): 107-113.
144. Xu J, et al.Somatic mutation analysis ofEGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer.Cancer Biomark. 2011;10 (2): 639.
145. Wu CC, et al.Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.Cancer. 2008;113 (11): 3199-208.
146. Pemer S, et al.EML4-ALK fusion lung cancer: a rare acquired event.Neoplasia. 2008;10 (3): 298-302.